RBC Capital analyst Daniel Busby maintained a Buy rating on Viatris on Monday, setting a price target of $23, which is approximately 52.32% above the present share price of $15.1.
Busby expects Viatris to post earnings per share (EPS) of -$0.86 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Viatris, with an average price target of $19.5.
The analysts price targets range from a high of $23 to a low of $16.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $4.43 billion and a net profit of -$243.3 million. The company's market cap is $18.25 billion.
According to TipRanks.com, RBC Capital analyst Daniel Busby is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -5.6% and a 40.63% success rate.
Mylan (NASDAQ:VTRS) NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.